Danaher (NYSE:DHR) Price Target Raised to $270.00 at Leerink Partners

Danaher (NYSE:DHR) had its price objective upped by equities researchers at Leerink Partners from $260.00 to $270.00 in a research report issued on Friday,MarketScreener reports. The firm presently has an “outperform” rating on the conglomerate’s stock. Leerink Partners’ price target indicates a potential upside of 14.38% from the stock’s current price.

DHR has been the subject of a number of other research reports. Jefferies Financial Group upped their price target on Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday, December 18th. TD Cowen boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Morgan Stanley assumed coverage on Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 target price for the company. Finally, HSBC boosted their price target on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Twenty-one research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $252.83.

Danaher Trading Down 1.6%

DHR stock opened at $236.05 on Friday. Danaher has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a market cap of $166.73 billion, a price-to-earnings ratio of 48.67, a PEG ratio of 4.27 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $228.31 and a 200-day simple moving average of $211.85.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $1.71 EPS. On average, equities research analysts expect that Danaher will post 7.63 EPS for the current year.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock valued at $6,609,663 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. JPL Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth about $25,000. WFA of San Diego LLC purchased a new position in shares of Danaher during the second quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher during the 2nd quarter worth $27,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher during the third quarter valued at about $27,000. Finally, TruNorth Capital Management LLC purchased a new position in Danaher in the third quarter valued at approximately $28,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.